Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2015

01-02-2015 | Original Article

Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases

Authors: Ashwin N. Ananthakrishnan, Alice Cheng, Andrew Cagan, Tianxi Cai, Vivian S. Gainer, Stanley Y. Shaw, Susanne Churchill, Elizabeth W. Karlson, Shawn N. Murphy, Isaac Kohane, Katherine P. Liao

Published in: Digestive Diseases and Sciences | Issue 2/2015

Login to get access

Abstract

Introduction

Inflammatory bowel diseases [IBD; Crohn’s disease (CD), ulcerative colitis] often affect women in their reproductive years. Few studies have analyzed the impact of mode of childbirth on long-term IBD outcomes.

Methods

We used a multi-institutional IBD cohort to identify all women in the reproductive age-group with a diagnosis of IBD prior to pregnancy. We identified the occurrence of a new diagnosis code for perianal complications, IBD-related hospitalization and surgery, and initiation of medical therapy after either a vaginal delivery or caesarean section (CS). Cox proportional hazards models adjusting for potential confounders were used to estimate independent effect of mode of childbirth on IBD outcomes.

Results

Our cohort included 360 women with IBD (161 CS). Women in the CS group were likely to be older and more likely to have complicated disease behavior prior to pregnancy. During follow-up, there was no difference in the likelihood of IBD-related surgery (multivariate hazard ratio 1.75, 95 % confidence interval (CI) 0.40–7.75), IBD-related hospitalization (HR 1.39), initiation of immunomodulator therapy (HR 1.45), or anti-TNF therapy (HR 1.11). Among the 133 CD pregnancies with no prior perianal disease, we found no excess risk of subsequent new diagnosis perianal fistulae with vaginal delivery compared to CS (HR 0.19, 95 % CI 0.04–1.05).

Conclusions

Mode of delivery did not influence natural history of IBD. In our cohort, vaginal delivery was not associated with increased risk of subsequent perianal disease in women with CD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.PubMedCrossRef Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.PubMedCrossRef
2.
go back to reference Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1–20.PubMedCrossRef Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1–20.PubMedCrossRef
3.
go back to reference Mountifield RE, Prosser R, Bampton P, et al. Pregnancy and IBD treatment: this challenging interplay from a patients’ perspective. J Crohns Colitis. 2010;4:176–182.PubMedCrossRef Mountifield RE, Prosser R, Bampton P, et al. Pregnancy and IBD treatment: this challenging interplay from a patients’ perspective. J Crohns Colitis. 2010;4:176–182.PubMedCrossRef
4.
go back to reference Selinger CP, Eaden J, Selby W, et al. Patients’ knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool (‘CCPKnow’). Aliment Pharmacol Ther. 2012;36:57–63.PubMedCrossRef Selinger CP, Eaden J, Selby W, et al. Patients’ knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool (‘CCPKnow’). Aliment Pharmacol Ther. 2012;36:57–63.PubMedCrossRef
5.
go back to reference Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7:e206–e213.PubMedCrossRef Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7:e206–e213.PubMedCrossRef
6.
go back to reference Agret F, Cosnes J, Hassani Z, et al. Impact of pregnancy on the clinical activity of Crohn’s disease. Aliment Pharmacol Ther. 2005;21:509–513.PubMedCrossRef Agret F, Cosnes J, Hassani Z, et al. Impact of pregnancy on the clinical activity of Crohn’s disease. Aliment Pharmacol Ther. 2005;21:509–513.PubMedCrossRef
7.
go back to reference Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004;270:79–85.PubMedCrossRef Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004;270:79–85.PubMedCrossRef
8.
go back to reference Friedman S, Regueiro MD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:265–273, xii. Friedman S, Regueiro MD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:265–273, xii.
9.
go back to reference Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease—a population-based cohort study. Am J Obstet Gynecol. 1997;177:942–946.PubMedCrossRef Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease—a population-based cohort study. Am J Obstet Gynecol. 1997;177:942–946.PubMedCrossRef
10.
go back to reference Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214–223; quiz 224. Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214–223; quiz 224.
11.
go back to reference Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161–173; quiz 174. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161–173; quiz 174.
12.
go back to reference Rogers RG, Katz VL. Course of Crohn’s disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Am J Perinatol. 1995;12:262–264.PubMedCrossRef Rogers RG, Katz VL. Course of Crohn’s disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Am J Perinatol. 1995;12:262–264.PubMedCrossRef
13.
14.
go back to reference Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.PubMedCrossRef Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.PubMedCrossRef
15.
go back to reference Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: evidence base and patients’ perspective. World J Gastroenterol. 2012;18:2600–2608.PubMedCentralPubMedCrossRef Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: evidence base and patients’ perspective. World J Gastroenterol. 2012;18:2600–2608.PubMedCentralPubMedCrossRef
16.
go back to reference Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.PubMedCrossRef Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.PubMedCrossRef
17.
go back to reference Hutson JR, Matlow JN, Moretti ME, et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33:1–8.PubMedCrossRef Hutson JR, Matlow JN, Moretti ME, et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33:1–8.PubMedCrossRef
18.
go back to reference Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947–957.PubMedCentralPubMedCrossRef Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947–957.PubMedCentralPubMedCrossRef
19.
go back to reference Allen VM, Baskett TF, O’Connell CM. Contribution of select maternal groups to temporal trends in rates of caesarean section. J Obstet Gynaecol Can. 2010;32:633–641.PubMed Allen VM, Baskett TF, O’Connell CM. Contribution of select maternal groups to temporal trends in rates of caesarean section. J Obstet Gynaecol Can. 2010;32:633–641.PubMed
20.
go back to reference Fairley L, Dundas R, Leyland AH. The influence of both individual and area based socioeconomic status on temporal trends in Caesarean sections in Scotland 1980–2000. BMC Public Health. 2011;11:330.PubMedCentralPubMedCrossRef Fairley L, Dundas R, Leyland AH. The influence of both individual and area based socioeconomic status on temporal trends in Caesarean sections in Scotland 1980–2000. BMC Public Health. 2011;11:330.PubMedCentralPubMedCrossRef
21.
go back to reference Roberts CL, Algert CS, Carnegie M, et al. Operative delivery during labour: trends and predictive factors. Paediatr Perinat Epidemiol. 2002;16:115–123.PubMedCrossRef Roberts CL, Algert CS, Carnegie M, et al. Operative delivery during labour: trends and predictive factors. Paediatr Perinat Epidemiol. 2002;16:115–123.PubMedCrossRef
22.
go back to reference Manosa M, Navarro-Llavat M, Marin L, et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013;48:427–432.PubMedCrossRef Manosa M, Navarro-Llavat M, Marin L, et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013;48:427–432.PubMedCrossRef
24.
go back to reference Hatch Q, Champagne BJ, Maykel JA, et al. Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum. 2014;57:174–178.PubMedCrossRef Hatch Q, Champagne BJ, Maykel JA, et al. Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum. 2014;57:174–178.PubMedCrossRef
25.
go back to reference Ilnyckyji A, Blanchard JF, Rawsthorne P, et al. Perianal Crohn’s disease and pregnancy: role of the mode of delivery. Am J Gastroenterol. 1999;94:3274–3278.PubMedCrossRef Ilnyckyji A, Blanchard JF, Rawsthorne P, et al. Perianal Crohn’s disease and pregnancy: role of the mode of delivery. Am J Gastroenterol. 1999;94:3274–3278.PubMedCrossRef
26.
go back to reference Smink M, Lotgering FK, Albers L, et al. Effect of childbirth on the course of Crohn’s disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol. 2011;11:6.PubMedCentralPubMedCrossRef Smink M, Lotgering FK, Albers L, et al. Effect of childbirth on the course of Crohn’s disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol. 2011;11:6.PubMedCentralPubMedCrossRef
27.
go back to reference Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn’s disease. Am J Gastroenterol. 1995;90:1918–1922.PubMed Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn’s disease. Am J Gastroenterol. 1995;90:1918–1922.PubMed
28.
go back to reference Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1921–1927.PubMedCentralPubMed Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1921–1927.PubMedCentralPubMed
29.
go back to reference Ananthakrishnan AN, Cagan A, Gainer VS, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014;8:956–963. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014;8:956–963.
30.
go back to reference Ananthakrishnan AN, Cai T, Savova G, et al. Improving case definition of Crohn’s disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis. 2013;19:1411–1420.PubMedCentralPubMedCrossRef Ananthakrishnan AN, Cai T, Savova G, et al. Improving case definition of Crohn’s disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis. 2013;19:1411–1420.PubMedCentralPubMedCrossRef
31.
go back to reference Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342–1348. Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342–1348.
32.
go back to reference Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:821–827. Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:821–827.
33.
go back to reference Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:445–454.PubMedCentralPubMedCrossRef Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:445–454.PubMedCentralPubMedCrossRef
34.
go back to reference Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med. 2004;351:2581–2589.PubMedCrossRef Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med. 2004;351:2581–2589.PubMedCrossRef
35.
go back to reference Cheng AG, Oxford EC, Sauk J, et al. The impact of mode of delivery on outcomes in patients with perianal Crohn’s disease. Inflamm Bowel Dis. 2014;20:1391–1398. Cheng AG, Oxford EC, Sauk J, et al. The impact of mode of delivery on outcomes in patients with perianal Crohn’s disease. Inflamm Bowel Dis. 2014;20:1391–1398.
Metadata
Title
Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases
Authors
Ashwin N. Ananthakrishnan
Alice Cheng
Andrew Cagan
Tianxi Cai
Vivian S. Gainer
Stanley Y. Shaw
Susanne Churchill
Elizabeth W. Karlson
Shawn N. Murphy
Isaac Kohane
Katherine P. Liao
Publication date
01-02-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3353-6

Other articles of this Issue 2/2015

Digestive Diseases and Sciences 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.